Nicolaus Radford, who founded Nauticus Robotics and took it all the way to IPO, shares details of his new company, PersonaAI. Image via LinkedIn

For his next act, Houston entrepreneur Nicolaus Radford has started — in what he describes as an "anti-stealth" capacity — a new company that hopes to bring humanoid robotics out of science fiction novels and into manufacturing floors.

Radford, who saw his last company, Nauticus Robotics, from founding to IPO, left the company in January. He tells InnovationMap that he started receiving some compelling offers at other robotics companies, but none of them felt like a fit. However, he just couldn't get the idea of advancing humanoid robotics out of his head.

"Humanoids are the holy grail of all of robotics," Radford says. "It's what every science fiction writer's always dreamed about.

"It is the future," he continues. "And now with this generative AI moment of 2022 where these machines look a lot more capable, flexible, reprogrammable — they can reason in real time. That's a huge deal."

Radford says he got a call from his friend, Jerry Pratt, who was the CTO at humanoid robotics company Figure AI. Pratt and Radford both worked in robotics at NASA and each have decades of experience in the tech world. The conversation really sealed the deal for Radford, and the two officially launched Persona AI in a LinkedIn post that Radford says shocked him with how much interest the community had.

Radford says that with all this interest, he wants to open up the company to more co-founders than just himself and Pratt, who's based in Florida.

"We're going to give a significant amount of the company out to the early joiners, more so than is probably typical," Radford says. "And it's because we know it takes a village, and we want to highlight that to everybody."

"We're trying to crowdsource the company," he continues. "We've coined that we're anti stealth."

Specifically, Radford says he's looking at growing the team to about 25 people in the next year, alongside raising early funding. He's looking for people with a diverse tech background with well-rounded experience.

"Robotics and humanoids in particular are just so multidisciplinary," Radford says. "Humanoids are a hundred-thousand-piece puzzle, and you're trying to put this puzzle together."

And for Radford, assembling that puzzle in Houston is of utmost importance. The company is headquartered here, and Radford is currently working with The Ion to set up an office there.

"We're exceptionally excited to put (the company) in Houston," he says. "It would be incredible for the city — there's a lot of industrial manufacturing here and a lot of warehousing. ... I still have this desire to shine a light on Houston's tech scene because I believe it is unsung, underappreciated, and quite capable."

The potential for this technology is huge — Radford estimates it as a $3 trillion market — but the first industry he plans on tackling is automotive, but he also sees promise in the medical, energy, and home industries.

"We think automotive is going to be a first-mover market. There's a lot of publicly announced partnerships between advanced robotics companies and humanoid companies and automotive," he says. "These folks are showing a willingness to put something out in the press that says they're developing a humanoid or piloting a humanoid. That's huge.

With this expressed interest, technology advancement, and large labor shortage, Radford is convinced now is the time for humanoid robotics — and for Persona AI.

"We're at a technology tipping point where it makes sense that these machines can do this, and there's an investment community willing to finance it," Radford says. "I think the first time in all of robotic history we're closer than we've ever been to making this a reality."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”